Desk› Healthcare› Piramal Pharma Ltd

Piramal Pharma Ltd

BSE 543635 PPLPHARMA INE0DK501011

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 30 trading days

19 filings · 6 material · busiest 2026-07-29

What it files

General5 Analyst / Investor Meet3 SAST2 AGM / EGM2 Acquisition1 Concall Transcript1 Board Outcome1 Results1

Filings

19 in the window

24 August 2026

General

Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26

Please refer attached file

Company Update / General View filing →
18 August 2026

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
18 August 2026

Acquisition

Acquisition

Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited

Company Update / Acquisition View filing →
10 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Company Update / Analyst / Investor Meet View filing →
10 August 2026

General

Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited

Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited

Company Update / General View filing →
3 August 2026

General

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Resumption Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat

Please refer attachment

Company Update / General View filing →
31 July 2026

Concall Transcript

Earnings Call Transcript

Please find enclosed details of Earning call Transcript held on 30th July 2026.

Company Update / Earnings Call Transcript View filing →
30 July 2026

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Please find enclosed intimation of audio recordings of the conference call held today 30th July, 2026.

Company Update / Analyst / Investor Meet View filing →
30 July 2026

AGM / EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings and Voting Results of the 6th Annual General Meeting of the Company

AGM/EGM / AGM View filing →
30 July 2026

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM

AGM/EGM / AGM View filing →
29 July 2026

General

Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Grant Of Stock Options

Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Inc entive Plan 2022

Company Update / General View filing →
29 July 2026

Board Outcome

Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 29Th July, 2026

Please find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July, 2026

Board Meeting / Outcome of Board Meeting View filing →
29 July 2026

Results

Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June, 2026

Please find enlcosed UFR Q1 FY 27.

Result / Financial Results View filing →
29 July 2026

Press Release

Press Release / Media Release

Please see enlcosed Press Release for Q1 FY 27

Company Update / Press Release / Media Release View filing →
29 July 2026

Investor Presentation

Investor Presentation

Please see enclosed Investor Presentation for Q1 FY 27

Company Update / Investor Presentation View filing →
24 July 2026

General

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Temporary Suspension Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat.

Please refer attachment.

Company Update / General View filing →
20 July 2026

Board Meeting

Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June, 2026.

Piramal Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....

Board Meeting / Board Meeting View filing →
20 July 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.

Company Update / Analyst / Investor Meet View filing →
17 July 2026

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →